Very interesting to see the evidence of the incredible ROI meeting with a Dietitian provides not only for the patient's health outcomes, but for Medicaid programs as well
And having both treatments managed under one experienced clinician helps keep your care joined-up, consistent, and personalised.
This FDA-approved medication is notable for its dual action on GLP-1 and GIP receptors, making it highly effective in reducing appetite and enhancing metabolism
However, patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use any GLP-1 receptor agonist
Common side effects reported in clinical trials and post-market surveillance include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite
Delgado-Aros et al